Source comparison
MK-677 vs Tesamorelin Which Better Comparison: Clinical Outcomes and Body Composition
IGF-1 Elevation 50–90% increase from baseline within 2 weeks; sustained non-pulsatile elevation 60–100% increase; restores physiological pulsatility Tesamorelin preserves natural GH feedback loops. More aligned with endogenous physiology Visceral Fat Reduction
This comparison does not assign a generated winner or score.
- IGF-1 Elevation
- 50–90% increase from baseline within 2 weeks; sustained non-pulsatile elevation
- 60–100% increase; restores physiological pulsatility
- Tesamorelin preserves natural GH feedback loops. More aligned with endogenous physiology
- Visceral Fat Reduction
- Minimal direct effect; lean mass gains without targeted abdominal fat loss
- 15–20% reduction in visceral adipose tissue (VAT) after 26 weeks at 2 mg daily (TRIM trial data)
- Tesamorelin is FDA-approved specifically for VAT reduction. MK-677 is not
- Lean Body Mass
- +2–3 kg gain over 12 months in elderly populations; primarily water retention and muscle glycogen
- +1.5 kg lean tissue gain; less water retention, more structural muscle
- MK-677 gains are front-loaded and partially reversible; tesamorelin gains are slower but more durable
- Appetite and Metabolic Effects
- Marked appetite increase (30–50% caloric intake rise); insulin resistance develops with chronic use
- No appetite stimulation; minimal impact on fasting glucose or insulin sensitivity
- For subjects managing caloric intake or insulin sensitivity, tesamorelin is the safer choice
- Administration Convenience
- Oral once daily; no injection, no refrigeration
- Subcutaneous injection daily; requires reconstitution and cold storage
- MK-677 wins on convenience. Tesamorelin wins on metabolic safety
- Bottom Line
- Best for lean mass gains, joint health, sleep quality. If appetite and insulin effects are manageable
- Best for targeted visceral fat reduction with preserved GH pulsatility and minimal metabolic disruption
- Choose based on primary outcome: lean mass and convenience = MK-677; abdominal fat and metabolic safety = tesamorelin
- The TRIM trial (Tesamorelin in the Reduction of Intermuscular Fat) demonstrated 15% reduction in visceral adipose tissue after 26 weeks of daily 2 mg tesamorelin injections in HIV-positive patients with abdominal lipodystrophy. An outcome MK-677 has never replicated in any published trial. MK-677's lean mass gains are well-documented but include significant water retention and intramuscular glycogen storage, which reverses partially upon discontinuation. Tesamorelin's lean tissue increases are slower but represent actual myofibrillar protein accretion with minimal fluid retention.